insight
✂️ 성형 🏥 중증 탈모 한방 반려 게놈 🌐 전체
← 뒤로

Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?

🦱 탈모
4/5 보강
The journal of sexual medicine 📖 저널 OA 11.1% 2021: 1/12 OA 2022: 1/22 OA 2023: 1/12 OA 2024: 3/15 OA 2025: 9/41 OA 2026: 10/31 OA 2021~2026 2007 Vol.4(6) p. 1708-12 피인용 29회 cited 295 RCR 6.57 Sexual function and dysfunction stud
TL;DR The burden of this nocebo effect (an adverse side effect that is not a direct result of the specific pharmacological action of the drug) has to be taken into account when managing finasteride sexual side effects.
Retraction 확인
출처
PubMed DOI OpenAlex Semantic 마지막 보강 2026-05-12

PICO 자동 추출 (휴리스틱, conf 2/4)

유사 논문
P · Population 대상 환자/모집단
2 patients was ".
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
A scenario similar to group 2 of the current study is likely to occur in clinical practice, where the patient is counseled by the physician and has access to the drug information sheet. The burden of this nocebo effect (an adverse side effect that is not a direct result of the specific pharmacological action of the drug) has to be taken into account when managing finasteride sexual side effects.
📑 코퍼스 인용 관계 · 인용됨 29
📑 인용한 논문 (6) ▾
연도별 인용 (2012–2026) · 합계 261
OpenAlex 토픽 · Sexual function and dysfunction studies Urinary Bladder and Prostate Research Pain Management and Placebo Effect

Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A

PubMed ↗ DOI ↗ BibTeX ↓ RIS ↓

Abstract

[INTRODUCTION] Sexual adverse experiences such as erectile dysfunction (ED), loss of libido, and ejaculation disorders have been consistent side effects of finasteride in a maximum percentage of 15% after 1 year of therapy. Such data could be seen as far from reality, if compared to a higher percentage that may be found in any common clinical practice.

[AIM] This study aims to explain the dichotomy between literature's data and clinical practice data.

[METHODS] One hundred twenty patients with a clinical diagnosis of benign prostatic hyperplasia (BPH), sexually active and with an International Index of Erectile Function-erectile function (IIEF-EF) domain >/=25 were randomized to receive finasteride 5 mg concealed as an "X compound of proven efficacy for the treatment of BPH" for 1 year with (group 2) or without (group 1) counseling on the drug sexual side effect. The phrase used to inform group 2 patients was ". . . it may cause erectile dysfunction, decreased libido, problems of ejaculation but these are uncommon".

[MAIN OUTCOME MEASURES] The estimation of side effect was conducted at 6 and 12 months using the male sexual function-4 (MSF-4 item) questionnaire and a self-administered questionnaire.

[RESULTS] One hundred seven patients completed the study. Group 2 patients (N = 55) reported a significant higher proportion of one or more sexual side effects as compared to group 1 (N = 52) (43.6% vs. 15.3%) (P = 0.03). The incidence of ED, decreased libido, and ejaculation disorders were 9.6, 7.7, and 5.7% for group 1, and 30.9, 23.6, and 16.3% for group 2, respectively (P = 0.02, P = 0.04, and P = 0.06).

[CONCLUSION] In the current study, blinded administration of finasteride was associated with a significantly higher proportion of sexual dysfunction in patients informed on sexual side effects (group 2) as compared to those in which the same information was omitted (group 1) (P = 0.03). A scenario similar to group 2 of the current study is likely to occur in clinical practice, where the patient is counseled by the physician and has access to the drug information sheet. The burden of this nocebo effect (an adverse side effect that is not a direct result of the specific pharmacological action of the drug) has to be taken into account when managing finasteride sexual side effects.
🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 표본수 (n) 55
  • p-value P = 0.03
  • p-value P = 0.02
📝 환자 설명용 한 줄

The burden of this nocebo effect (an adverse side effect that is not a direct result of the specific pharmacological action of the drug) has to be taken into account when managing finasteride sexual s

이 논문을 인용하기

↓ .bib ↓ .ris
APA 7 Mondaini, N., Gontero, P., Giubilei, G., Lombardi, G., Cai, T., Gavazzi, A., & Bartoletti, R. (2007). Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon?. The journal of sexual medicine, 4(6), 1708-12. https://doi.org/10.1111/j.1743-6109.2007.00563.x
Vancouver Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?. jour. sexu. medi.. 2007;4(6):1708-12. doi:10.1111/j.1743-6109.2007.00563.x
AMA 11 Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?. jour. sexu. medi.. 2007;4(6):1708-12. doi:10.1111/j.1743-6109.2007.00563.x
Chicago Mondaini, N., Gontero, P., Giubilei, G., Lombardi, G., Cai, T., Gavazzi, A., and Bartoletti, R.. 2007. "Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?." The journal of sexual medicine 4 (6): 1708-12. https://doi.org/10.1111/j.1743-6109.2007.00563.x
MLA 9 Mondaini, N., et al. "Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon?." The journal of sexual medicine, vol. 4, no. 6, 2007, pp. 1708-12. doi:10.1111/j.1743-6109.2007.00563.x.
PMID 17655657 ↗
DOI 10.1111/j.1743-6109.2007.00563.x

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

인용 관계

그래프 OA 노드: 7/8 (88%) · 참조 0편 · 후속 7편

이 논문을 인용한 후속 연구 20

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반